SG Americas Securities LLC Purchases 13,803 Shares of Zoetis Inc. $ZTS

SG Americas Securities LLC raised its position in Zoetis Inc. (NYSE:ZTS) by 5.0% in the first quarter, HoldingsChannel.com reports. The fund owned 290,332 shares of the company’s stock after purchasing an additional 13,803 shares during the quarter. SG Americas Securities LLC’s holdings in Zoetis were worth $34,320,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of ZTS. Global Wealth Strategies & Associates acquired a new position in shares of Zoetis during the 4th quarter worth about $25,000. Prosperity Bancshares Inc acquired a new stake in Zoetis in the 4th quarter valued at about $25,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis during the third quarter worth about $31,000. Lodestone Wealth Management LLC acquired a new position in Zoetis during the fourth quarter worth approximately $30,000. Finally, Elyxium Wealth LLC acquired a new position in Zoetis during the fourth quarter worth approximately $32,000. Institutional investors own 92.80% of the company’s stock.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Pomerantz, Howard G. Smith, Rosen, Kessler Topaz, Glancy Prongay Wolke & Rotter, the Gross Law Firm, and Schall Law Firm all issued notices about a class action lawsuit and July 27 lead-plaintiff deadline for Zoetis investors, keeping legal risk in focus. Article: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors…
• Negative Sentiment: Another report said Zoetis shareholders who lost money may seek to lead a securities-fraud lawsuit, adding to the overhang on the stock. Article: Zoetis Inc. (ZTS) Shareholders Who Lost Money…
• Neutral Sentiment: Brokerage commentary still shows an average Hold rating, suggesting analysts are not broadly turning bullish yet. Article: Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of “Hold”…

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research reports. JPMorgan Chase & Co. cut their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Argus reissued a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Stifel Nicolaus cut their target price on shares of Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research note on Friday, May 22nd. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 target price on shares of Zoetis in a report on Friday, May 15th. Finally, Citigroup decreased their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Zoetis presently has an average rating of “Hold” and an average price target of $133.92.

Insider Transactions at Zoetis

In other Zoetis news, Director Michael B. Mccallister purchased 3,000 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 11,650 shares of company stock valued at $886,384. Corporate insiders own 0.22% of the company’s stock.

Zoetis Stock Up 1.3%

ZTS stock opened at $76.85 on Wednesday. The company has a market cap of $32.22 billion, a PE ratio of 12.74, a price-to-earnings-growth ratio of 1.18 and a beta of 0.75. The business has a 50-day simple moving average of $91.31 and a 200 day simple moving average of $111.78. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $161.77. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period last year, the business earned $1.48 earnings per share. The business’s revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.